Berlin Startup Offers Cryopreservation as a Bet on Future Medicine
A Berlin-based startup, Tomorrow Biostasis, has secured €5 million in seed funding to advance cryopreservation services—offering individuals the option to be stored at –196°C after legal death, with the aim of potential revival when scientific capabilities allow. Founded in 2020 by Dr. Emil KendziorraDealroom has a profile for this one. Try Dealroom → and Fernando Azevedo PinheiroDealroom has a profile for this one. Try Dealroom →, the company has already preserved 20 humans and 10 pets, with more than 800 people enrolled in pre-arranged contracts. The service is structured around rapid-response teams, termed “cryo-ambulances,” which stabilise the body immediately after legal death, replacing fluids with cryoprotectants and transporting it to a long-term storage facility in Rafz, Switzerland.
The process does not involve experimental treatments or anti-aging interventions. Instead, it relies on well-established cryogenic methods using liquid nitrogen and vacuum-insulated storage. Clients are preserved in steel dewars that require no electricity and maintain ultra-low temperatures indefinitely. The company currently operates in Europe but is expanding into the United States, targeting locations in New York, California, and Florida.
While cryonics remains controversial and its scientific viability unproven, the model put forward by Tomorrow Biostasis has attracted attention due to its structured logistics, clear pricing (approximately $200,000 per patient), and growing interest in life-extension technologies. The concept also raises complex societal and legal questions, including the future of inheritance, healthcare, and population dynamics, should reanimation ever become possible. As co-founder Kendziorra puts it, the company’s mission is not to prevent death but to offer “lifespan choice”—an option to wait for future cures rather than accept biological limits today.
Source:
A.M.
